Advertiser / Brand · Direct-to-Consumer (D2C) Brand · vs · Advertiser / Brand
AG1 vs P&G
Structured technology and market comparison · 2026
Direct Feature Comparison
AG1 · vs · P&GD2C nutrition brand selling a daily greens supplement.
Global consumer goods company selling household and personal care brands.
Analyze all overlapping signals and tech stacks for AG1 and P&G
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between AG1 and P&G?
When comparing AG1 and P&G, both platforms operate within the Advertiser / Brand ecosystem. AG1 is positioned as D2C nutrition brand selling a daily greens supplement, whereas P&G focuses on Global consumer goods company selling household and personal care brands. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to AG1 and P&G?
When evaluating AG1 and P&G, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of AG1 and P&G compare?
AG1 is headquartered in US (founded in 2010) with 501–1,000 employees. P&G is based in US (founded in 1837) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: AG1 vs P&G
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
AG1
Recent Signals
- ·Modern RetailE-commerce / Brand Strategy
Brands Use Clinical Research as Growth Engine
Supplement and cleaning brands like AG1, Ritual, and Blueland are increasingly funding their own clinical research to differentiate products, boost advertising performance, and gain retail shelf space. These companies conduct or commission studies published in peer-reviewed journals, using findings to support marketing claims and product development. For instance, AG1 committed $20 million to research, while Ritual has invested over $5 million in studies. Such research helps brands combat misinformation, appeal to data-driven consumers, and satisfy wholesale buyers demanding third-party validation. Although there is no official FTC definition of 'clinical,' companies follow guidelines requiring competent scientific evidence for health claims. This strategy serves as a long-term brand investment, with executives noting higher-performing ads and stronger retail positioning as outcomes.
- AG1 committed $20 million to support three years of gut health and nutrient gap research.
- Ritual has invested at least $5 million in clinical studies and employed up to 20 full-time positions for research.
- Ritual completed at least five clinical studies, three peer-reviewed and published.
P&G
Recent Signals
- ·HorizontFinancials
US Ad Giants Cut Ad Spending Share to 5.5%
The WARC Global Ad Trends report titled 'The cost of being seen' analyzed the advertising-to-sales ratio of 25 major US advertisers, including Coca-Cola and P&G. The analysis reveals that the average ad-to-sales ratio has declined to 5.5%. This indicates a reduction in advertising intensity among large US corporations. Concurrently, WARC Media forecasts global ad spending to increase by 11.9% in 2026 to $1.34 trillion. The report highlights a strategic shift as brands allocate budgets more efficiently, possibly influenced by economic pressures and the need for greater ROI.
- WARC analyzed 25 major US advertisers including Coca-Cola and P&G.
- The average ad-to-sales ratio fell to 5.5%.
- WARC Media forecasts global ad spending to rise by 11.9% in 2026 to $1.34 trillion.
- ·SEC APIfinancials
8-K Financial Filing Analysis for P&G (2026-10-13)
On October 13, 2026, The Procter & Gamble Company announced via Form 8-K that its Board of Directors declared a quarterly dividend of $1.0885 per share on both its Common Stock and Series A and Series B ESOP Convertible Class A Preferred Stock. The dividend is scheduled for payment on or after November 16, 2026, to Common Stock shareholders of record as of the close of business on October 23, 2026, and to ESOP Preferred shareholders of record at the opening of business on the same date. Concurrently, the Company announced that preliminary voting results from its Annual Meeting of Shareholders confirmed the successful election of all twelve director nominees to the Board of Directors.
- Declared a quarterly dividend of $1.0885 per share on Common Stock and Series A and Series B ESOP Convertible Class A Preferred Stock.
- Set the dividend record date for October 23, 2026, with distributions payable on or after November 16, 2026.
- Confirmed the election of all twelve Director nominees to the Board of Directors based on preliminary Annual Meeting voting results.
- ·SEC APIfinancials
10-K Financial Filing Analysis for P&G (2026-08-04)
Procter & Gamble (P&G) reported its full-year financial results for the fiscal year ended June 30, 2026. Consolidated net sales increased 3% year-over-year to $87.03 billion, supported by 1% organic sales growth and a 2% favorable foreign exchange impact. Operating income decreased 3% to $19.75 billion due to a 100-basis-point decline in gross margin to 50.2% and higher marketing spending in SG&A. Net earnings rose slightly to $16.14 billion ($16.05 billion attributable to P&G), with diluted EPS improving 2% to $6.62, aided by share repurchases and non-operating gains including $261 million from the expiration and dissolution of the Glad joint venture interest. Operating cash flow remained strong at $19.56 billion, supporting $15.84 billion in adjusted free cash flow (100% productivity). The company continued executing its multi-year portfolio and productivity plan, incurring $903 million after tax in restructuring costs in fiscal 2026. P&G also announced an agreement on August 4, 2026, to acquire premium supplement brand Thorne for $3.8 billion.
- Net sales grew 3% to $87,032 million (organic sales up 1%), while net earnings attributable to P&G reached $16,046 million with diluted EPS of $6.62 (Core EPS of $6.89).
- Operating cash flow reached $19,556 million, delivering $15,835 million in adjusted free cash flow and achieving an adjusted free cash flow productivity rate of 100%.
- Subsequent to fiscal year-end on August 4, 2026, P&G signed an agreement to acquire premium wellness brand Thorne for $3.8 billion.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners AG1 and P&G share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks